# A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

> **NCT06242652** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 250 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** 608 Dose A
- **DRUG:** 608 Dose B
- **DRUG:** 608 Dose C
- **DRUG:** Adalimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06242652
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-19
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-06-15
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06242652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06242652, "A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06242652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*